Trial record 10 of 26 for:
rhBMP-2 | Industry
Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease
This study has been completed.
Sponsor:
Medtronic Spinal and Biologics
Information provided by (Responsible Party):
Medtronic Spinal and Biologics
ClinicalTrials.gov Identifier:
NCT01494441
First received: December 12, 2011
Last updated: December 15, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.
| Condition | Intervention |
|---|---|
|
Degenerative Disc Disease |
Procedure: rhBMP-2/BCP Device: rhBMP-2/BCP/TSRH® Spinal System Device: Autograft/TSRH® Spinal System |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease |
Resource links provided by NLM:
MedlinePlus related topics:
Calcium
Drug Information available for:
Calcium Gluconate
U.S. FDA Resources
Further study details as provided by Medtronic Spinal and Biologics:
Primary Outcome Measures:
- Fusion [ Time Frame: 24 month ] [ Designated as safety issue: No ]
Fusion is defined as:
- Evidence of bridging trabecular bone.
- No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographas determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs;
- Absence of radiolucent lines completely through the fusion mass.
- Pain/Disability Status [ Time Frame: 24 month ] [ Designated as safety issue: No ]The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
Secondary Outcome Measures:
- Neurological Status Success [ Time Frame: 24 month ] [ Designated as safety issue: No ]Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.
- Hip (Donor Site) Pain [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- General Health Status (SF-36) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Pain Status (back pain, leg pain) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient Satisfaction [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient Global Perceived Effect [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Overall Success [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
| Enrollment: | 27 |
| Study Start Date: | May 1999 |
| Study Completion Date: | March 2003 |
| Primary Completion Date: | March 2003 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: rhBMP-2/BCP |
Procedure: rhBMP-2/BCP
The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Other Names:
|
| Experimental: rhBMP-2/BCP/TSRH® Spinal System |
Device: rhBMP-2/BCP/TSRH® Spinal System
rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
Other Names:
|
| Active Comparator: Autograft/TSRH® Spinal System |
Device: Autograft/TSRH® Spinal System
The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
Other Name: Autograft
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:
- instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score > 30.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
- Requires fusion of a single level disc space from L1 to S1.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
- Had previous spinal fusion surgical procedure at the involved level.
- Require spinal fusion at more than one lumbar level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
- Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy.
- Has overt or active bacterial infection, either local or systemic.
- Is grossly obese, i.e., weight > 40% over ideal for their age and height.
- Has fever ( temperature >101°F oral) at the time of surgery.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Is a tobacco user at the time of surgery.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
- Has received any previous exposure to any/all BMPs of either human or animal extraction.
- Has a history of severe allergy (anaphylaxis).
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Medtronic Spinal and Biologics |
| ClinicalTrials.gov Identifier: | NCT01494441 History of Changes |
| Other Study ID Numbers: | C-9805 |
| Study First Received: | December 12, 2011 |
| Last Updated: | December 15, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Medtronic Spinal and Biologics:
|
lumbar degenerative disc disease |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
Calcium, Dietary Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013